COMMUNIQUÉS West-GlobeNewswire

Actinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory Affairs

14/03/2018 - 12:30

Dr. Rowlands joins Actinium with almost two decades of experience as a regulatory affairs strategist specialized in the development of first-in-class therapeutics for the treatment of rare and/or serious conditions with [...]

Cellular Biomedicine Group Announces Upcoming Presentation to Release 48-Week Data from Phase I Clinical Trial for AlloJoin™ Off-the-Shelf Allogeneic Stem Cell Therapy for Knee Osteoarthritis

14/03/2018 - 12:30

SHANGHAI, China and CUPERTINO, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (NASDAQ: CBMG ) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of [...]

Voyager Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

14/03/2018 - 12:02

VY-AADC for advanced Parkinson’s disease on track for start of planned global, pivotal Phase 2-3 program during the middle of this year Two IND filings expected from the ALS, Huntington’s disease and Friedreich’s ataxia [...]

Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference

14/03/2018 - 12:01

Summit Therapeutics plc ("Summit" or the "Company") Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference Oxford, UK, and Cambridge, MA, US, 14 March 2018 - Summit [...]

ContraFect to Present at the 20th Annual Superbugs & Superdrugs UK Conference

14/03/2018 - 12:00

YONKERS, New York, March 14, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX ), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life [...]

Merus Announces Ono Pharmaceuticals Exercise of its Option for New Research and License Agreement to Generate Bispecific Antibody Targeting Autoimmune Diseases

14/03/2018 - 12:00

UTRECHT, The Netherlands, March 14, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that [...]

Easton Pharmaceuticals Announces It Has Commenced Negotiations With An AMPR Applicant Towards a Marijuana Cultivators / Growers License For Canada; Provides iBliss Update

14/03/2018 - 12:00

TORONTO, ON, March 14, 2018 (GLOBE NEWSWIRE) -- Easton Pharmaceuticals Inc. (OTC: EAPH) announces it has commenced negotiations with an AMPR applicant towards a Canadian Marijuana cultivators / growers license. Provides [...]

Nabriva Therapeutics to Present at the Needham and Company 17th Annual Healthcare Conference

14/03/2018 - 12:00

DUBLIN, Ireland and KING OF PRUSSIA, Pa., March 14, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV ), a clinical stage biopharmaceutical company engaged in the research and development of novel anti- [...]

BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference

14/03/2018 - 12:00

RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI ), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that [...]

Summit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical Conference

14/03/2018 - 12:00

OXFORD, United Kingdom and CAMBRIDGE, Mass., March 14, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT ) (AIM:SUMM) highlighted the rigour being utilised in the collection and analysis of muscle biopsies [...]

Clearside Biomedical Announces Fourth Quarter 2017 Financial Results and Provides Corporate Update

14/03/2018 - 12:00

ALPHARETTA, Ga., March 14, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ: CLSD ), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases [...]

Cesca’s Device Subsidiary, ThermoGenesis, Expands into CAR-T Related Contract Development and Manufacturing (CDMO) Services

14/03/2018 - 12:00

RANCHO CORDOVA, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ: KOOL ), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today [...]

Olainfarm will hold Fourth Quarter 2017 Investor Conference Webinar

14/03/2018 - 11:10

Olaine, 2018-03-14 11:10 CET (GLOBE NEWSWIRE) -- Webinar will be hosted by the Member of the Management Board Salvis Lapiņš. The presentation will be held in English. During the webinar Salvis Lapiņš will inform about [...]

Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology

14/03/2018 - 09:10

Curetis Receives USPTO Notice of Allowance for Key Patent Covering Unyvero Technology IP position strengthened in the U.S. Patent supports utility of Unyvero Lysator Technology for sample preparation Amsterdam, the [...]

Bio-on launches U-COAT, a company operating in the fertilisers market with a biodegradable controlled-release solution.

14/03/2018 - 08:11

The new company, U-COAT S.p.A. , will sell an innovative solution for the controlled release of Urea fertilisers into the soil. The innovation was developed by Bio-on with PHAs bioplastics, so it is 100% natural and [...]

Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference

14/03/2018 - 08:08

Kiadis Pharma to Present at the Cowen and Company 38th Annual Health Care Conference Amsterdam, The Netherlands, March 14, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company") (Euronext Amsterdam and Brussels: [...]

DBV Technologies Reports Full Year 2017 Financial Results

14/03/2018 - 07:31

Montrouge, France, March 14, 2018 DBV Technologies Reports Full Year 2017 Financial Results DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced full year 2017 results. Audit [...]

Résultats Financiers 2017 de DBV Technologies

14/03/2018 - 07:31

Montrouge, France, le 14 mars 2018 (7h30 CET) Résultats Financiers 2017 de DBV Technologies DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - NASDAQ : DBVT), société biopharmaceutique française, a annoncé aujourd [...]

Conditions financières améliorées de l'accord entre Nicox et Bausch + Lomb pour VYZULTA

14/03/2018 - 07:31

Communiqué de presse Conditions financières améliorées de l'accord entre Nicox et Bausch + Lomb pour VYZULTA TM Augmentation des redevances de 1% sur les ventes annuelles mondiales de VYZULTA TM dépassant 300 millions [...]